Drug intelligence / Profile preview

Serocen

Development stage
Unknown
Lead developer
Indusbiotech
Modality
Small Molecules
Administration
Oral
01

Overview

Serocen is a nutraceutical ingredient and dietary supplement developed by Indus Biotech (Indus Group). It is a highly purified botanical extract derived from *Centella asiatica* L. (Gotu Kola), standardized to contain at least 50% total triterpenoid glycosides, specifically asiaticoside and madecassoside. Administered orally, Serocen is designed to act as a blocker of the 5HT-1a (serotonin) receptor to prevent serotonin reuptake, thereby increasing serotonin levels in the bloodstream. It is indicated for the management of depression, anxiety, and mood disorders by promoting mood elevation and reducing stress-related cortisol levels. The product is manufactured using the proprietary Natrusolate technology, which utilizes cane alcohol and water extraction for plants cultivated in Madagascar.

Brand names
Serocen
Other names
Centella asiatica extract
02

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR1B (5-Hydroxytryptamine Receptor 1B)

Beyond the preview

Go deeper on Serocen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serocen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call